Skip to content

Impact of Fever Prevention in Brain Injured Patients (INTREPID)

Impact of Fever Prevention in Brain Injured Patients (INTREPID) - INTREPID Study

Status
Unknown
Phases
Phase 4
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON46804
Enrollment
40
Registered
2018-04-09
Start date
Unknown
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

brain injury stroke

Interventions

Sponsors

C.R. Bard
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: * Adult patients >80 and

Exclusion criteria

Exclusion criteria: * Fever (>= 38°C) for more than one hour prior to study enrollment * Pre-existing neurological, psychiatric, or other condition that would confound neurological assessment or would make it difficult to accurately assess neurologic and/or functional outcome * Has a pre-morbid condition that in the opinion of the investigator suggests poor likelihood of survival to 6 months * Is undergoing therapeutic hypothermia therapy * Has sustained neurological injury felt to be catastrophic with little chance of recovery or is on comfort measures only * Has a skin condition in which the use of the ArcticGel Pads is contraindicated * Participation in a concurrent interventional study * In the investigator*s opinion is likely to stay in the ICU = 38°C) at time of study enrollment

Design outcomes

Primary

MeasureTime frame
The primary outcome endpoint is the daily average fever burden (°C-hour) between randomization and Day 14 (336 hours) or ICU exit, whichever comes first. The key secondary outcome endpoint (to which the study was powered) is the level of functional independence at 90 days post-injury (3-month) follow-up based on the modified Rankin Scale.

Secondary

MeasureTime frame
* Neurologic outcome measures - Modified Rankin Scale measured at 6- and 12-months - National Institutes of Health Stroke Scale measured at 3- and 6-months - Barthel Index measured at 3- and 6-months - Glasgow Outcome Scale Extended measured at 3- and 6-months - Montreal Cognitive Assessment measured at 3- and 6-months * Intensive Care Unit length of stay * ICU Delirium * Use of mechanical ventilation * Hospital length of stay * Mortality [7-day (or hospital discharge), 3-, 6-, and 12-month]

Countries

Australia, Austria, Germany, Korea (the Republic of), Switzerland, United Kingdom, United States of America

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)